Darifenacin
- Generic Name
- Darifenacin
- Brand Names
- Emselex, Enablex
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30N2O2
- CAS Number
- 133099-04-4
- Unique Ingredient Identifier
- APG9819VLM
- Background
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention.
It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00171145
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00170768
- Locations
- 🇺🇸
Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
- Conditions
- Urinary Incontinence
- Interventions
- Behavioral: Behavioral therapy
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2008-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 395
- Registration Number
- NCT00127270
- Locations
- 🇺🇸
Research Protocol Management Specialists, Pittsburgh, Pennsylvania, United States
🇺🇸Southern Oregon Health and Wellness, Medford, Oregon, United States
🇺🇸Urologic Surgery Associates, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.